(206 days)
The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire), respiration rate (RESP), heart rate (HR), non-invasive blood pressure (NIBP), non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.
The ViSi Mobile Monitoring System is a lightweight, portable patient vital signs monitor featuring a high resolution, full color touch screen display, with visual and audible alarms and alerts. The ViSi Mobile Monitor is body-worn and designed to continuously measure ECG, heart rate, SpO2, pulse rate, respiration rate, and temperature. The ECG, SpO2, and Respiration waveforms are viewable on demand. NIBP can be measured as a onetime measurement, or it can be measured automatically at predefined intervals
The provided text describes the Sotera Wireless ViSi Mobile Monitoring System and references a clinical study for its NIBP measurement method. However, it does not provide explicit acceptance criteria with specific numerical performance targets or detailed results of a study that directly proves the device meets these criteria in a tabulated format.
The text states:
"The validity of this method [NIBP measurement on inflation] was confirmed in an ISO 81060-2 compliant clinical study demonstrating that this method of blood pressure meets the requirements of the standard in terms of accuracy and variability."
Based on this, here's what can be inferred and what information is missing:
1. Table of Acceptance Criteria and Reported Device Performance
| Parameter | Acceptance Criteria (from ISO 81060-2) | Reported Device Performance |
|---|---|---|
| NIBP | Meets requirements of ISO 81060-2 for accuracy and variability | "meets the requirements of the standard in terms of accuracy and variability" |
Missing Information: Specific numerical values for accuracy (e.g., mean difference and standard deviation) and variability (e.g., standard deviation of differences) as defined by ISO 81060-2 are not provided in the document.
2. Sample Size and Data Provenance for the Test Set
- Sample Size: Not specified for the NIBP clinical study.
- Data Provenance: Not specified (e.g., country of origin, retrospective or prospective). However, clinical studies for medical devices are typically prospective.
3. Number of Experts and Qualifications for Ground Truth
- This question is not applicable in the context of device performance testing against a standard like ISO 81060-2 for NIBP. The "ground truth" for blood pressure measurement in such studies typically refers to a reference method (e.g., intra-arterial catheter) or a highly accurate sphygmomanometer used by trained clinicians, not "experts" establishing a diagnosis. The document does not specify the ground truth method.
4. Adjudication Method for the Test Set
- Not applicable in this context. Testing against a standard for a physiological measurement device usually involves comparing the device's readings to a reference method, not an adjudication process by multiple experts.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
- No, an MRMC comparative effectiveness study was not done, or at least not described in this document. This type of study is more common for diagnostic imaging AI systems where human readers interpret medical images. The ViSi Mobile Monitoring System is a vital signs monitor, not an image interpretation device.
6. Standalone Performance Study
- Yes, a standalone study was performed. The NIBP clinical study is a standalone performance study, as it evaluates the device's ability to measure blood pressure against a standard, without human interpretation of the output.
7. Type of Ground Truth Used
- The document states the NIBP method "meets the requirements of the standard in terms of accuracy and variability." While not explicitly stated, the ground truth for an ISO 81060-2 compliant clinical study for NIBP typically involves:
- Simultaneous measurements: The device under test and a validated reference method (e.g., intra-arterial measurement or a highly accurate auscultatory method performed by trained operators) are used simultaneously.
8. Sample Size for the Training Set
- Not applicable as this document describes performance testing of a medical device against a standard, not the development of an AI model that requires a training set.
9. How the Ground Truth for the Training Set Was Established
- Not applicable (see point 8).
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows a sequence of handwritten characters and numbers. The sequence starts with the letter 'K', followed by the number '1' twice, then the numbers '2', '4', '7', and '8'. The characters are written in a simple, slightly irregular style, typical of handwriting.
MAR 2 2 2012
Image /page/0/Picture/2 description: The image shows the logo for Sotera Wireless. The logo consists of the word "Sotera" in a bold, sans-serif font, with a small graphic above the word. The graphic appears to be a stylized representation of radio waves. Below the word "Sotera" is the word "WIRELESS" in a smaller, sans-serif font.
510(k) Summary
| Date prepared | November 20, 2011 |
|---|---|
| Name | Sotera Wireless. Inc.9444 Waples Street, Suite 280San Diego, CA 92121T. 858.427.4620; F. 858.427.4639 |
| Contact person | Eben GordonSenior Director, Regulatory |
| Trade name | ViSi Mobile Monitoring System |
| Common name | Vital signs monitor |
| Classification name | Cardiac monitor (including cardiotachometer and rate alarm) |
| Classification regulation | Monitor, physiological, patient(without arrhythmia detection or alarms; 21CFR 870.2300 (MWI) |
| Predicate device | Nihon Kohden ZS-940PAK043517, Clearance date: February 3, 2005 |
| Omron Healthcare, Inc., HBP-2070K082812, Clearance date: October 22, 2008 | |
| Description | The ViSi Mobile Monitoring System is a lightweight, portable patient vitalsigns monitor featuring a high resolution, full color touch screen display,with visual and audible alarms and alerts. The ViSi Mobile Monitor isbody-worn and designed to continuously measure ECG, heart rate, SpO2,pulse rate, respiration rate, and temperature. The ECG, SpO2, andRespiration waveforms are viewable on demand. NIBP can be measured asa onetime measurement, or it can be measured automatically at predefinedintervals |
| Indications for use | The ViSi Mobile Monitoring System is intended for use by clinicians andmedically qualified personnel for single or multi-parameter vital signsmonitoring of adult patients. It is indicated for ECG (3 or 5 leadwire),respiration rate (RESP), heart rate (HR), non-invasive blood pressure(NIBP), non-invasive monitoring of functional oxygen saturation of arterialhemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) inhospital-based facilities; including general medical-surgical floors,intermediate care floors, and emergency departments. |
| Summary of substantialequivalence | The ViSi System has the following similarities and differences with theindicated predicate devices: |
| Intended use - The ViSi System and the predicate devices have thesame intended uses as the predicate devices: vital signs monitoring. |
{1}------------------------------------------------
While NIBP is measured using oscillation for all three devices, the ViSi System determines blood pressure on inflation rather than deflation. The validity of this method was confirmed in an ISO 81060-2 compliant clinical study demonstrating that this method of blood pressure meets the requirements of the standard in terms of accuracy and variability.
The Nihon Kohden device has the capability to transmit data wirelessly in addition to local display and alarming while the ViSi System differs in that it only has the capability to display and alarm locally (i.e. does not transmit data wirelessly). Similar to the Omron HBP-2070, the ViSi does not transmit data for remote viewing.
-
Design ViSi System and the Nihon Kohden ZS-940PA have . similar form factors in that they both are patient worn. The Omron HBP-2070 is not attached to the patient.
The safety and effectiveness of the design elements implemented into the ViSi System have been confirmed by their compliance to the prevailing vital signs monitoring standards. The ViSi System has demonstrated compliance with the applicable sections of the following consensus standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-1-4, IEC 60601-1-8, IEC 60601-2-27, IEC 60601-2-49, IEC 80601-2-30, ISO 9919, ASTM E1112, EC13, and EC53. -
General Safety and Effectiveness Concerns The instructions for . use for the ViSi System contains the necessary cautions and warnings to provide for safe and effective use of the device.
The ViSi System has successfully undergone safety testing as well as functional testing to demonstrate equivalence to the predicate devices. The following quality assurance measures were applied to the device: Risk analysis, Requirements review, Code inspections, Verification and validation, Bench testing, Clinical performance testing, Biocompatibility testing, and Safety testing
The ViSi System have been tested and found to comply with recognized national and international performance, safety, and electromagnetic compatibility standards for medical devices. The results of all the testing demonstrate that the ViSi System is safe, effective, complies with the appropriate medical device standards, and is substantially equivalent to the predicate devices.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three stylized, curved lines.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
MAR 2 2 2012
Sotera Wireless, Inc. c/o Mr. Eben Gordon Sr. Director, Regulatory Affairs 9444 Waples St., Suite 280 San Diego, CA 92121
Re: K112478
Trade/Device Names: Visi Mobile Monitoring System, Model (H1,1a) Regulatory Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (including Cardiotachometer and Rate Alarm) Regulatory Class: Class II (Two) Product Code: MWI, DRT, DXN, DQA and FLL Dated: March 2, 2012 Received: March 5, 2012
Dear Mr. Gordon:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Mr. Eben Gordon
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
4 INDICATIONS FOR USE
510(k) Number (if known):
Device Name: ______________________________________________________________________________________
Indications for Use:
The ViSi Mobile Monitoring System is intended for use by clinicians and medically qualified personnel for single or multi-parameter vital signs monitoring of adult patients. It is indicated for ECG (3 or 5 leadwire), respiration rate (RESP), heart rate (HR), non-invasive blood pressure (NIBP), non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2), pulse rate (PR), and skin temperature (TEMP) in hospital-based facilities; including general medical-surgical floors, intermediate care floors, and emergency departments.
Prescription Use __
AND/OR
Over the Counter Use _________________________________________________________________________________________________________________________________________________________
(Part 21 CFR 801 Subpart D)
(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Cardiovascular Devices |
| Page 1 of 1 | |
|---|---|
| -- | ------------- |
| 8/25/2011 | 510(k) Number K112478 | Page 12 |
|---|---|---|
| ----------- | ----------------------- | --------- |
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).